AVBP
NASDAQ · Biotechnology
Arrivent Biopharma Inc
$31.74
+0.38 (+1.21%)
Open$32.70
Previous Close$31.36
Day High$32.80
Day Low$31.43
52W High$33.62
52W Low$16.10
Volume—
Avg Volume485.9K
Market Cap1.48B
P/E Ratio—
EPS$-3.52
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-19.3% upside
Current
$31.74
$31.74
Target
$25.60
$25.60
$15.99
$25.60 avg
$32.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 217.05M | 207.22M | 172.47M |
| Net Income | -33,899,494 | -32,015,874 | -32,580,881 |
| Profit Margin | -15.6% | -15.5% | -18.9% |
| EBITDA | -52,835,285 | -48,435,254 | -38,009,184 |
| Free Cash Flow | -36,657,940 | -37,197,569 | -30,385,570 |
| Rev Growth | +1.9% | +19.8% | +13.5% |
| Debt/Equity | 0.28 | 0.20 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |